SRA-36 

SRA-36 is a CLC-K chloride channel inhibitor with selectivity over CLC-5 and CLC-1 chloride channels. SRA-36 blocks CLC-Ka currents with an IC₅₀ of 6.6 μM and a K_d of 3.8 μM. SRA-36 blocks chloride currents mediated by targeted channels, and inhibits currents from hypertension-associated CLC-Ka^A447T and CLC-Ka^Y315F polymorphisms. SRA-36 can be used for the research of hypertension^[1].

SRA-36 potently inhibits chloride currents from wild-type CLC-Ka channels heterologously expressed in HEK293 cells, with an IC₅₀ of 6.6 μM^[1].
SRA-36 potently inhibits chloride currents from wild-type CLC-Ka channels heterologously expressed in MDCK cells, with an apparent K_D of 3.8 μM^[1].
SRA-36 potently inhibits chloride currents from CLC-Kb and rat CLC-K1 channels heterologously expressed in HEK293 cells, reducing currents by ~90% at 50 μM^[1].
SRA-36 (5 μM) does not inhibit chloride currents from CLC-5 or CLC-1 channels heterologously expressed in HEK293 cells at a concentration of 5 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

328.36

C₂₂H₁₆O₃

OC(C1=C(C2=CC(CC3=CC=CC=C3)=CC=C2O1)C4=CC=CC=C4)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liantonio A, et al. Kidney CLC-K chloride channels inhibitors: structure-based studies and efficacy in hypertension and associated CLC-K polymorphisms. J Hypertens. 2016;34(5):981-992.  [Content Brief]